1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.

Voor meer informatie: http://www.quirem.com/

Other news

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

Cooperation RTM-Alliance Medical

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

LinkedIn post ESRR2024

📢 Important update on EU #GMP Annex 1 at #ESRR2024!  The revised EU GMP Annex 1, effecti...

News